CYTO Live signaler | Maksimer profitt med Getagraph.com

SELG 113361 min ago

@ $1.986

Utstedt: 9 feb 2024 @ 21:25

Avkastning: -14.90%

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 22:00):

Stats
Dagens volum	165 623
Gjennomsnittsvolum	1.19M
Markedsverdi	3.79M
EPS	$0 ( 2024-04-10 )
Neste inntjeningsdato	( $0 ) 2024-05-16
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.100
ATR14	$0.0200 (1.16%)

Insider Trading

Date	Person	Action	Amount	type
2008-05-08	Carter Stephen	Sell	10 000	Common Stock
2008-05-08	Lokay Kevin G	Sell	185 439	Common Stock
2008-05-08	Lokay Kevin G	Sell	100 000	Options to Purchase Common Stock
2008-05-08	Mollica Joseph A	Sell	10 000	Common Stock
2007-11-13	Lokay Kevin G	Buy	500 000	Options to purchase Common Stock par value $0.01

INSIDER POWER
0.00
Last 33 transactions
Buy: 1 218 228 \| Sell: 315 439

Volum Korrelasjon

Lang: 0.15 (neutral)

Kort: 0.32 (neutral)

Signal:(49.4) Neutral

Altamira Therapeutics Korrelasjon

10 Mest positive korrelasjoner
PIII	0.951
PROC	0.95
DISH	0.948
LGMK	0.945
AHCO	0.944
LGHL	0.942
EVLO	0.942
TTEC	0.941
MDRX	0.941
UPC	0.94

10 Mest negative korrelasjoner
VKTX	-0.965
JMAC	-0.965
IQ	-0.96
DKDCA	-0.96
CMPO	-0.957
HHGC	-0.956
IVCP	-0.956
AIB	-0.951
OVLY	-0.951
ACLS	-0.951

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Altamira Therapeutics Korrelasjon - Valuta/Råvare

-0.80
( strong negative )

-0.63
( weak negative )

0.00
( neutral )

-0.66
( moderate negative )

0.00
( neutral )

-0.01
( neutral )

Altamira Therapeutics Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$0 (0.00 %)
EPS:	$-14.80

FY	2023
Omsetning:	$0
Bruttogevinst:	$0 (0.00 %)
EPS:	$-14.80

FY	2022
Omsetning:	$305 616
Bruttogevinst:	$-1.14M (-372.44 %)
EPS:	$-29.13

FY	2021
Omsetning:	$63 882.00
Bruttogevinst:	$-2.18M (-3 407.33 %)
EPS:	$-3.24

Financial Reports:

No articles found.

Altamira Therapeutics

Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, including OligoPhore and SemaPhore platforms that are in preclinical stage for oligonucleotide and mRNA delivery; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It operates in Switzerland, the United States, Europe, and Australia. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. Altamira Therapeutics Ltd. was founded in 2003 and is headquartered in Hamilton, Bermuda.